These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 12017536)
1. The role of mitoxantrone in non-Hodgkin's lymphoma. Armitage JO Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536 [TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
3. The role of mitoxantrone in the treatment of indolent lymphomas. Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217 [TBL] [Abstract][Full Text] [Related]
4. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704 [TBL] [Abstract][Full Text] [Related]
5. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959 [TBL] [Abstract][Full Text] [Related]
6. CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). Björkholm M; Andersson T; Ahlbom A; Ösby E Eur J Haematol; 2008 Jun; 80(6):477-82. PubMed ID: 18331601 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762 [TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771 [TBL] [Abstract][Full Text] [Related]
9. [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result]. Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K Gan To Kagaku Ryoho; 1986 Sep; 13(9):2813-9. PubMed ID: 3530138 [TBL] [Abstract][Full Text] [Related]
10. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127 [TBL] [Abstract][Full Text] [Related]
11. [A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission]. Itoh T; Sakata Y; Suzuki H; Sugimoto N; Sohma N; Kishibe T; Higuchi S; Seino Y Gan To Kagaku Ryoho; 1992 Feb; 19(2):241-4. PubMed ID: 1371049 [TBL] [Abstract][Full Text] [Related]
12. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256 [TBL] [Abstract][Full Text] [Related]
13. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
14. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma. Wilder DD; Ogden JL; Jain VK Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762 [TBL] [Abstract][Full Text] [Related]
18. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy]. López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196 [TBL] [Abstract][Full Text] [Related]
20. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Guglielmi C; Gherlinzoni F; Amadori S; Mazza P; Mantovani L; Lauria F; Martelli M; Zinzani PL; Greco V; Poletti G Haematologica; 1989; 74(6):563-9. PubMed ID: 2483401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]